

Provider Notice

December 1, 2022

Illinois Preferred Drug List – Upcoming 2023 Formulary Updates

On January 1, 2020, all MCOs were required to adopt the Illinois HFS Preferred Drug List to align with the Fee for Service program. As a result of a changes to the Illinois HFS Preferred Drug List, the following agents (label name) will no longer be preferred. Table 1. below details which agents (label name) will no longer be preferred and the preferred formulary alternatives for transitioning members to new options. Table 2. details agents changing to Preferred or Preferred with PA.

Table 1. Effective February 1, 2023, ENBREL products will REQUIRE PRIOR AUTHORIZATION:

LABEL NAME	THERAPEUTIC CLASS	PREFERRED FORMULARY ALTERNATIVES ¹	PA REQUIRED (YES/NO)
ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML), RECON SOLN 25 MG (1 ML) ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML)	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	HUMIRA (BRAND): HUMIRA & HUMIRA (CF) PEN CROHNS-UC-HS STARTER PEN INJECTOR KIT & SC PEN INJECTOR KIT 40 MG/0.8 ML, 80 MG/0.8 ML HUMIRA PEN PSOR-UVEITS-ADOL HS & (CF) SC PEN INJECTOR KIT 40 MG/0.8 ML, 40MG/0.4 ML, 80MG/0.8ML HUMIRA & HUMIRA CF PEN SC PEN INJECTOR KIT 40MG /0.4 ML, 80MG/0.8 ML HUMIRA SC SYRINGE KIT 40 MG/0.8 ML HUMIRA(CF) PEDI CROHNS STARTER SC SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML HUMIRA(CF) PEN PEDIATRIC UC SC PEN INJECTOR KIT 80 MG/0.8 ML HUMIRA(CF) SC SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML CIMZIA (BRAND): CIMZIA STARTER KIT SC SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) CIMZIA SC SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)	YES

[†]SC = Subcutaneous

Current CountyCare Formulary [Effective October 2022] can be found here: https://countycare.com/wp-content/uploads/October-2022-Formulary.pdf

Table 2. EFFECTIVE JANUARY 1, 2023



Provider Notice

December 1, 2022

	December 1, 2022						
	LABEL NAME	THERAPEUTIC CLASS	PREVIOUS	NEW STATUS			
	HUMIRA & HUMIRA (CF)	ANTI-INFLAMMATORY	FORMULARY STATUS PREFERRED WITH PA	FORMULARY STATUS PREFERRED			
	PEN CROHNS-UC-HS	TUMOR NECROSIS	FILE LINED WITH FA	FILLILINED			
	STARTER PEN INJECTOR	FACTOR INHIBITOR					
	KIT & SC PEN INJECTOR						
	KIT 40 MG/0.8 ML, 80						
	MG/0.8 ML						
	HUMIRA PEN PSOR-						
	UVEITS-ADOL HS & (CF)						
	SC PEN INJECTOR KIT 40						
	MG/0.8 ML, 40MG/0.4 ML, 80MG/0.8ML						
	IVIL, 801VIG/U.8IVIL						
	HUMIRA & HUMIRA CF						
	PEN SC PEN INJECTOR KIT						
	40MG /0.4 ML, 80MG/0.8 ML						
	IVIL						
	HUMIRA SC SYRINGE KIT						
	40 MG/0.8 ML						
	HUMIRA(CF) PEDI						
	CROHNS STARTER SC						
	SYRINGE KIT 80 MG/0.8						
	ML, 80 MG/0.8 ML-40						
	MG/0.4 ML						
	HUMIRA(CF) PEN						
	PEDIATRIC UC SC PEN						
	INJECTOR KIT 80 MG/0.8						
	ML						
	HUMIRA(CF) SC SYRINGE						
	KIT 10 MG/0.1 ML, 20						
	MG/0.2 ML, 40 MG/0.4						
ŀ	ML COSENTYX SENSOREADY	DERMATOLOGICALS:	NON- PREFERRED	PREFERRED WITH PA			
	AUTO-INJECTOR PEN	ANTIPSORIATICS	NON- PREFERRED	PREFERRED WITH PA			
	150MG/ML						
	COSENTYX PRE-FILLED						
	SYRINGE 75MG/0.5ML,						
	150MG/1ML						
L		ould be reflected in the leavens ?		l			

Note: Above Formulary changes would be reflected in the January 2023 PDL document.

We look forward to working with you to ensure uninterrupted care for our members.

Please contact Cookcountyhhs.org for additional information or assistance.